{"transactions":[{"id":879239,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-26T21:15:23.000Z","date":"2026-02-24","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":60000,"derivative":{"exercise_price":15.52,"expiration_date":"2036-02-23","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001682068-26-000005","document":"form4-02262026_040214.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000168206826000005/form4-02262026_040214.xml","form_type":"4"}},{"id":890168,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-20T21:15:07.000Z","date":"2026-02-18","kind":"sale","planned":false,"acquired":false,"shares":4739,"price":16.35,"value":77482.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":39261,"source":{"system":"sec-edgar","filing":"0001682068-26-000003","document":"form4-02202026_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000168206826000003/form4-02202026_040201.xml","form_type":"4"}},{"id":1258542,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-19T21:15:15.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award.  The RSUs vest as follows: 33% of the RSUs shall vest on February 17, 2026, an additional 34% of the total number of RSUs shall vest on August 15, 2026, and the remaining 33% of the total number of RSUs shall vest on February 16, 2027, in each case, subject to the Reporting Person's Continuous Service (as defined in the 2020 Plan) through each applicable vesting date."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0001415889-25-004597","document":"form4-02192025_040209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000141588925004597/form4-02192025_040209.xml","form_type":"4"}},{"id":1295340,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-24T21:15:08.000Z","date":"2024-01-04","kind":"sale","planned":false,"acquired":false,"shares":40000,"price":45.29,"value":1811600.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This amendment is being filed to correct the Date of Earliest Transaction and the Transaction Date of each transaction listed in Table I."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-002024","document":"form4a-01242025_040104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000141588925002024/form4a-01242025_040104.xml","form_type":"4/A","original_submission_date":"2024-01-08"}},{"id":1295339,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-24T21:15:08.000Z","date":"2024-01-04","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":16,"value":640000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This amendment is being filed to correct the Date of Earliest Transaction and the Transaction Date of each transaction listed in Table I."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001415889-25-002024","document":"form4a-01242025_040104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000141588925002024/form4a-01242025_040104.xml","form_type":"4/A","original_submission_date":"2024-01-08"}},{"id":1640518,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-16T01:40:02.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on February 13, 2025, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":40000,"derivative":{"exercise_price":56.18,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-004003","document":"form4-02162024_010256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000141588924004003/form4-02162024_010256.xml","form_type":"4"}},{"id":1683629,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-08T21:43:46.000Z","date":"2024-01-04","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":53622,"derivative":{"exercise_price":16,"expiration_date":"2030-04-06","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-24-001155","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919124001155/doc4.xml","form_type":"4"}},{"id":1683628,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:43:46.000Z","date":"2023-11-04","kind":"sale","planned":false,"acquired":false,"shares":40000,"price":45.29,"value":1811600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-24-001155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919124001155/doc4.xml","form_type":"4"}},{"id":1683627,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:43:46.000Z","date":"2023-11-04","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":16,"value":640000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001209191-24-001155","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919124001155/doc4.xml","form_type":"4"}},{"id":1858244,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-06-12T20:13:40.000Z","date":"2023-06-09","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":93622,"derivative":{"exercise_price":16,"expiration_date":"2030-04-06","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-036261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919123036261/doc4.xml","form_type":"4"}},{"id":1858243,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-06-12T20:13:40.000Z","date":"2023-06-08","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":113622,"derivative":{"exercise_price":16,"expiration_date":"2030-04-06","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-036261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919123036261/doc4.xml","form_type":"4"}},{"id":1858242,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-12T20:13:40.000Z","date":"2023-06-09","kind":"sale","planned":true,"acquired":false,"shares":2579,"price":47.25,"value":121857.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.015 to $47.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-036261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919123036261/doc4.xml","form_type":"4"}},{"id":1858241,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-12T20:13:40.000Z","date":"2023-06-09","kind":"sale","planned":true,"acquired":false,"shares":1428,"price":46.46,"value":66344.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.015 to $47.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2579,"source":{"system":"sec-edgar","filing":"0001209191-23-036261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919123036261/doc4.xml","form_type":"4"}},{"id":1858240,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-12T20:13:40.000Z","date":"2023-06-09","kind":"sale","planned":true,"acquired":false,"shares":15993,"price":45.03,"value":720164.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.995 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4007,"source":{"system":"sec-edgar","filing":"0001209191-23-036261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919123036261/doc4.xml","form_type":"4"}},{"id":1858239,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-12T20:13:40.000Z","date":"2023-06-09","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":16,"value":320000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-23-036261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919123036261/doc4.xml","form_type":"4"}},{"id":1858238,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-12T20:13:40.000Z","date":"2023-06-08","kind":"sale","planned":true,"acquired":false,"shares":2699,"price":48.65,"value":131306.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.12 to $48.935 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-036261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919123036261/doc4.xml","form_type":"4"}},{"id":1858237,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-12T20:13:40.000Z","date":"2023-06-08","kind":"sale","planned":true,"acquired":false,"shares":17301,"price":47.66,"value":824565.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.12 to $48.095 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2699,"source":{"system":"sec-edgar","filing":"0001209191-23-036261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919123036261/doc4.xml","form_type":"4"}},{"id":1858236,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-12T20:13:40.000Z","date":"2023-06-08","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":16,"value":320000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-23-036261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919123036261/doc4.xml","form_type":"4"}},{"id":2006390,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-17T21:14:30.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on February 16, 2024, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":40000,"derivative":{"exercise_price":54.38,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-010557","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919123010557/doc4.xml","form_type":"4"}},{"id":2426344,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-01-25T21:15:37.000Z","date":"2022-01-21","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares subject to the option shall vest on January 19, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":50000,"derivative":{"exercise_price":46.3,"expiration_date":"2032-01-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-004767","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919122004767/doc4.xml","form_type":"4"}},{"id":2909042,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-01-12T22:25:49.000Z","date":"2021-01-10","kind":"grant","acquired":true,"shares":49150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares subject to the option shall vest on January 7, 2022, and one-twelfth (1/12th) of the remaining shares subject\nto the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such\ndate."}],"balance_after":49150,"derivative":{"exercise_price":70.93,"expiration_date":"2031-01-09","underlying":"Common Stock","underlying_shares":49150},"source":{"system":"sec-edgar","filing":"0001209191-21-003274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919121003274/doc4.xml","form_type":"4"}},{"id":3179470,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-04-09T01:02:34.000Z","date":"2020-04-07","kind":"grant","acquired":true,"shares":133622,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":133622,"derivative":{"exercise_price":16,"expiration_date":"2030-04-06","underlying":"Common Stock","underlying_shares":133622},"source":{"system":"sec-edgar","filing":"0001209191-20-023990","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919120023990/doc4.xml","form_type":"4"}},{"id":3179469,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-04-09T01:02:34.000Z","date":"2020-04-07","kind":"grant","acquired":true,"shares":18430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares subject to the option shall vest on March 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":18430,"derivative":{"exercise_price":16,"expiration_date":"2030-04-06","underlying":"Common Stock","underlying_shares":18430},"source":{"system":"sec-edgar","filing":"0001209191-20-023990","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1664710/000120919120023990/doc4.xml","form_type":"4"}},{"id":3601133,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2019-03-11T23:19:17.000Z","date":"2019-03-07","kind":"grant","acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted share units (RSUs).  The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023."}],"balance_after":29186,"source":{"system":"sec-edgar","filing":"0000899243-19-007114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924319007114/doc4.xml","form_type":"4"}},{"id":3640979,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2019-02-22T00:54:47.000Z","date":"2019-02-19","kind":"sale","acquired":false,"shares":1298,"price":36.8396,"value":47817.8008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 19, 2019, the reporting person sold 1,298 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2019. These sales were made pursuant to a 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $36.83 to $37.4582 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":15686,"source":{"system":"sec-edgar","filing":"0000899243-19-004467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924319004467/doc4.xml","form_type":"4"}},{"id":3807046,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (right to buy)","published_at":"2018-09-26T22:59:51.000Z","date":"2018-09-24","kind":"exercise","acquired":false,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The share option represented a right to purchase a total of 120,000 ordinary shares, 25% of which became exercisable on August 16, 2017, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":90500,"derivative":{"exercise_price":20.89,"expiration_date":"2026-08-16","underlying":"Ordinary Shares","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0000899243-18-025320","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924318025320/doc4.xml","form_type":"4"}},{"id":3807045,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2018-09-26T22:59:51.000Z","date":"2018-09-24","kind":"sale","acquired":false,"shares":29500,"price":55,"value":1622500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018."}],"balance_after":16984,"source":{"system":"sec-edgar","filing":"0000899243-18-025320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924318025320/doc4.xml","form_type":"4"}},{"id":3807044,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2018-09-26T22:59:51.000Z","date":"2018-09-24","kind":"exercise","acquired":true,"shares":29500,"price":20.89,"value":616255.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The share option represented a right to purchase a total of 120,000 ordinary shares, 25% of which became exercisable on August 16, 2017, and the remaining shares vest in 36 equal monthly installments thereafter."}],"balance_after":46484,"source":{"system":"sec-edgar","filing":"0000899243-18-025320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924318025320/doc4.xml","form_type":"4"}},{"id":4043305,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2018-02-22T00:16:01.000Z","date":"2018-02-16","kind":"sale","acquired":false,"shares":316,"price":51.85,"value":16384.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 16, 2018, the reporting person sold 316 ordinary shares solely to cover taxes associated with the vesting of restricted share units on February 15, 2018. These sales were made pursuant to a 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $51.65 to $51.85 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":16984,"source":{"system":"sec-edgar","filing":"0000899243-18-004949","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924318004949/doc4.xml","form_type":"4"}},{"id":4089442,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (right to buy)","published_at":"2018-01-26T01:06:03.000Z","date":"2018-01-23","kind":"grant","acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the shares on February 15, 2019 and vests as to an additional 6.25% of the shares quarterly thereafter until February 15, 2022."}],"balance_after":26000,"derivative":{"exercise_price":40.05,"expiration_date":"2028-01-23","underlying":"Ordinary Shares","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0000899243-18-002040","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924318002040/doc4.xml","form_type":"4"}},{"id":4089441,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2018-01-26T01:06:03.000Z","date":"2018-01-23","kind":"grant","acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted share units (RSUs).  The RSUs vest in four equal annual installments of 25% on February 15, 2019, through February 15, 2022."}],"balance_after":17300,"source":{"system":"sec-edgar","filing":"0000899243-18-002040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924318002040/doc4.xml","form_type":"4"}},{"id":4478817,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (right to buy)","published_at":"2017-01-27T23:14:38.000Z","date":"2017-01-25","kind":"grant","acquired":true,"shares":8600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the shares on February 15, 2018 and vests as to an additional 2.0833% of the shares monthly thereafter until February 15, 2021."}],"balance_after":8600,"derivative":{"exercise_price":29.05,"expiration_date":"2027-01-25","underlying":"Ordinary Shares","underlying_shares":8600},"source":{"system":"sec-edgar","filing":"0000899243-17-002146","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924317002146/doc4.xml","form_type":"4"}},{"id":4478816,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":64437,"kind":"person","name":"Regnante Keith","position":1,"cik":"0001682068","reported_name":"Regnante Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2017-01-27T23:14:38.000Z","date":"2017-01-25","kind":"grant","acquired":true,"shares":4300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted share units (RSUs).  The RSUs vest in four equal annual installments of 25% on February 15, 2018, through February 15, 2021."}],"balance_after":4300,"source":{"system":"sec-edgar","filing":"0000899243-17-002146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924317002146/doc4.xml","form_type":"4"}}]}